vadimezan has been researched along with thalidomide in 11 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (thalidomide) | Trials (thalidomide) | Recent Studies (post-2010) (thalidomide) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 9,789 | 1,385 | 4,342 |
| Protein | Taxonomy | vadimezan (IC50) | thalidomide (IC50) |
|---|---|---|---|
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 7.8 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.37 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.5 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.38 | |
| Protein cereblon | Homo sapiens (human) | 1.38 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Baguley, BC; Ching, LM; Gummer, BH; Joseph, WR; Palmer, BD; Xu, ZF | 1 |
| Baguley, BC; Browne, WL; Ching, LM; Gregory, T; Palmer, BD; Tchernegovski, R | 1 |
| Baguley, BC; Browne, WL; Cao, Z; Ching, LM; Joseph, WR; Mountjoy, KG; Palmer, BD | 1 |
| Baguley, BC; Ching, LM; Kestell, P; Muller, G; Palmer, BD; Paxton, JW; Zhao, L | 1 |
| Ching, LM; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S | 2 |
| Baguley, BC; Ching, LM; Chung, F; Kestell, P; Man, HW; Muller, GW; Palmer, BD | 1 |
| Baguley, BC; Ching, LM; Chung, F; Kestell, P; Wang, LC | 1 |
| Baguley, BC; Ching, LM; Chung, F; Liu, J | 1 |
| Ching, LM; Connor, B; Guise, C; McGregor, A; Seyfoddin, V; Tijono, S; Yung, R | 1 |
11 other study(ies) available for vadimezan and thalidomide
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Interactions; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Thalidomide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1995 |
Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Synergism; Mice; Neoplasm Transplantation; Pentoxifylline; Phthalimides; Thalidomide; Time Factors; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1998 |
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Synergism; Female; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; RNA, Messenger; Spleen; Thalidomide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1999 |
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bile; Colonic Neoplasms; Female; Half-Life; Mice; Mice, Inbred C57BL; Stereoisomerism; Thalidomide; Time Factors; Tissue Distribution; Xanthenes; Xanthones | 2000 |
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Diclofenac; Drug Interactions; Female; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Protein Binding; Teratogens; Thalidomide; Xanthenes; Xanthones | 2001 |
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Topics: Animals; Antineoplastic Agents; Cyproheptadine; Diclofenac; Drug Interactions; Glucuronides; Hydroxylation; Male; Mice; Microsomes, Liver; Rats; Rats, Wistar; Thalidomide; Xanthenes; Xanthones | 2001 |
Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Angiogenesis Inhibitors; Animals; Colonic Neoplasms; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Female; Injections, Intraperitoneal; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Molecular Structure; Neoplasm Transplantation; Stereoisomerism; Structure-Activity Relationship; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha; Xanthones | 2003 |
Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Topics: Animals; Area Under Curve; Cyclophosphamide; Drug Interactions; Mice; Mice, Inbred C57BL; Thalidomide; Tumor Necrosis Factor-alpha; Xanthones | 2004 |
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Topics: Animals; Antineoplastic Agents; Body Temperature; Capillary Permeability; Colonic Neoplasms; Coloring Agents; Drug Synergism; Evans Blue; Hematocrit; Liver Circulation; Mice; Mice, Inbred C57BL; Thalidomide; Xanthones | 2008 |
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Glioma; Infusions, Subcutaneous; Lenalidomide; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Random Allocation; Thalidomide; Xanthones | 2014 |